Pharmafile Logo

Understanding Patient Willingness to Pay

January 6, 2016 | emerging markets 

Published in eyeforpharma 12 October by Rachel Howard

What steps should pharma and medical device companies take to ensure they get their pricing strategy right in self-pay markets?

A key feature of emerging markets is that patients often have to self-fund a high proportion of their healthcare costs. For all but the most severe conditions, public reimbursement of pharmaceutical products and personal medical devices is often partial to non-existent, particularly in the outpatient setting. While private health insurance coverage is increasing in many emerging markets, penetration typically remains low, even among middle to high income segments of the population. This means that for many drugs and devices, the primary means of purchasing in emerging markets will be patients paying out of pocket. Any successful pricing strategy therefore needs to start with an understanding of target patients’ willingness to pay for the drug / device in question.

In this article, I partner with Research Partnership Quantitative Director and pricing expert Duncan Munro to set out the critical success factors that should be considered in order to determine how a medical product should be priced in a self-pay market.

Read the full article here:
www.researchpartnership.com/news/2015/10/article-understanding-patient-willingness-to-pay/


This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Infographic: Therapy Watch Acute Myeloid Leukemia market snapshot

This Acute Myeloid Leukemia infographic offers a snapshot of the real-world patient insights collected by our Therapy Watch study, based on data collected from a panel of 220 physicians across...

Research conducted for Johnson and Johnson published in scientific journal

Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, has been published in Clinical Genitourinary Cancer.

Connecting our Inizio Advisory capabilities to help a client address a threat to the brand, guide strategy and improve brand performance

The challenge Our client knew that prescribing of a key brand in a major market had slowed and needed to understand which patient segments were impacted so they could address...

Autoimmune conditions: Living With syndicated patient reports

The prevalence of autoimmune conditions is increasing, and despite significant advancements in treatments, individuals affected by these diseases may not be receiving the most effective management and care. In our...

How we elevated HCP market research engagement and insights using AI avatars for an immersive experience

Our client required an effective strategy for promoting discussions about self-paid vaccines with healthcare professionals (HCPs) during patient consultations. The conventional method of conducting market research would typically only deliver...

How we provided comprehensive real-world patient data for PAH using Therapy Watch, our syndicated market tracking solution

PAH is a specific type of pulmonary hypertension, which is a rare condition treated primarily in specialized centers. Our client needed to gain a comprehensive understanding of PAH patients, such...

Latest European developments and new talent at Research Partnership

Angela Duffy has been appointed as Managing Director for our European based ad hoc research teams. Angela has been an integral part of Research Partnership for 19 years, witnessing its...

New syndicated report – Living with Ulcerative Colitis 2024

Living with Ulcerative Colitis (UC) is a new syndicated patient report that presents valuable insights into the unmet needs and the burden experienced by patients living with UC. The report...